We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Insights Into Antibiotic Resistance

By HospiMedica staff writers
Posted on 24 Aug 2005
Researchers working with large-scale computer simulations have discovered a tiny change in molecular structure that may account for drug resistance in Streptomices pneumoniae, the organism that causes childhood pneumonia and claims 3.5 million lives a year, mainly in developing countries.

Until now, no experiments have been conducted to find how changes at the molecular level are causing this resistance. More...
The new finding may be very useful in designing new drugs that are effective against the drug-resistant strain. It was discovered by Prof. Peter Coveny and co-workers from the University College London (UK) and Queen Mary, University of London (UK), using computer modeling techniques. The results of their work were published in the August 15, 2005, issue of a special theme issue of Philosophical Transactions of the Royal Society.

The researchers took experimental data gathered from other organisms to build computer models of the sites where drug molecules interact with an organism's protein molecules. Then they ran simulations and visualized what happens when a drug molecule approaches each site for both normal and drug-resistant strains of S pneumoniae. The simulations and visualizations exploited highly scalable parallel code, running on the UK's national supercomputing facilities.

Prof. Coveny and his colleagues could see that a very small but subtle difference in structure beween the normal and drug-resistant strains was to blame for the drug resistance. In the normal strain, a drug molecule binds tightly to the site, but in the drug-resistant strain, it approaches and then drifts slowly away. The researchers believe this finding may point the way to new drugs that can combat disease.




Related Links:
University College London
Queen Mary, University of London

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.